AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01482416 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo group will use placebo once/day during 30 days
Study NCT04904211 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Home-based chemotherapy
Description: To investigate the feasibility and safety of home-based intensive chemotherapy in patients with newly diagnosed acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS). Furthermore, we examined the quality of life (QOL) and psychological wellbeing while receiving induction and consolidation chemotherapy at home.
Study NCT03485144 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TV003
Description: Live attenuated virus vaccine-TetraVax-DV
Study NCT03485144 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for TV003
Description: Placebo
Study NCT02018419 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AlloStim
Description: AlloStim is derived from the blood of normal blood donors and is intentionally mismatched to the recipient.
Study NCT02018419 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: Percutaneous ablation of a single metastatic tumor lesion usually in liver or bone. The procedure is conducted under CT or ultrasound image-guidance.
Study NCT01935765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Polysomnography
Description: Diabetes people: Examination diagnosis of the sleep apnea A night at the hospital
Study NCT01935765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation of the autonomous nervous system
Description: blood pressure, Heart frequence, deep breath, Orthostatism, Vasalva, Low blood pressure orthostatic
Study NCT01935765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical examination of the sleep
Description: Functional signs, collection of medical histories and associated pathologies, Pittsburgh Sleep Quality Index PSQI, Functional Outcomes of Sleep Questionnaire FOSQ, Epworth Sleepiness Scale ESS, Hospital Anxiety and Depression scale HAD
Study NCT01935765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical examination of diabetology
Description: history of diabet, observance, ophthalmological, renal, macroangiopathic and neuronal complications, Toronto scale, Diabetes Quality of Life (DQOL) Questionnaire
Study NCT01935765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological dosages
Description: Hematology, glycemia, lipids, CRP, creatinine, ferritin, glycosylated hemoglobin, transaminase, microalbuminuria, urine test
Study NCT01935765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electrocardiogram (ECG)
Description: Electrocardiogram (ECG)
Study NCT01935765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Carotid echography
Description: Carotid echography
Study NCT01935765 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood pressure
Description: Blood pressure
Study NCT04076644 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TMS treatment
Description: TMS using either a standard 10hz 20min or 3 min theta burst protocol
Study NCT04208906 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Masimo O3
Description: After anesthesia induction, a masimo O3 sensors are attached to the forehead (ScO2) and the sole of the foot (StO2). About 0.4 ml blood samples are obtained from arterial line and central venous line at three epochs before and after cardiopulmonary bypass (total 6 times)~* T1: before cardiopulmonary bypass (CPB), fraction of inspired oxygen (FiO2) 0.2~* T2: before CPB, FiO2 0.5~* T3: before CPB, FiO2 0.8~* T4: after CPB, FiO2 0.8~* T5: after CPB, FiO2 0.5~* T6: after CPB, FiO2 0.2~Hemoglobin oxygen saturation values are confirmed in each sample (arterial sample: SaO2, venous sample: SvO2). Each O3 values (ScO2 and StO2) are compared to the values of SvO2, 0.7 × SvO2 + 0.3 × SaO2.
Study NCT03342976 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: My-AHA platform
Description: ICT strategy for early detection of frailties
Study NCT03342976 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: My-AHA platform
Description: ICT strategy for early detection of frailties
Study NCT03491618 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PAIN REDUCTION ON VAS/NRS
Description: Pain reduction comparing two different techniques and canulae placement, under fluoroscopic guidance.
Study NCT01892930 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic body radiation therapy
Description: Undergo SBRT
Study NCT01892930 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo partial or radical nephrectomy
Study NCT01892930 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04433468 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RIPC
Description: The tourniquet attached to the upper limb was inflated and blocked for 5 minutes, then deflated for 5 minutes to restore blood flow and induce ischemic preconditioning.
Study NCT00720941 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pazopanib
Description: 800 mg administered once daily orally continuous dosing
Study NCT00720941 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sunitinib
Description: 50 mg sunitinib to be administered in 6-week cycles: 50mg orally daily for 4 weeks followed by 2 weeks off treatment
Study NCT02121587 — intervention group
Intervention type: BEHAVIORAL
Intervention: Pain self-management course
Description: This is an observational study of patient-reported outcomes from an experiential pain self-management course which integrates mindfulness and acceptance-based exercises into osteopathic manual therapy treatment. The intervention consists of six, individual, one-hour osteopathic evaluation and treatment sessions which incorporate pain education, the development of mindfulness skills to enhance body awareness, and the identification of personal values to promote compassionate self-care and sustain commitment to active coping strategies. The intervention aims to enhance patients' well-being and resilience through developing psychological and behavioural flexibility in response to persistent pain.
Study NCT03026257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lotrafilcon B contact lenses with added wetting agent
Description: Silicone hydrogel contact lenses
Study NCT03026257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Samfilcon A contact lenses
Description: Habitual silicone hydrogel contact lenses
Study NCT03026257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent
Description: Multi-purpose disinfecting solution for contact lens care
Study NCT03026257 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide-based contact lens solution with added wetting agent
Description: Solution for contact lens cleaning and disinfecting
Study NCT03026257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Senofilcon C contact lenses
Description: Habitual silicone hydrogel contact lenses
Study NCT03026257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Senofilcon A contact lenses
Description: Habitual silicone hydrogel contact lenses with a replacement pair issued after 2 weeks
Study NCT03026257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Comfilcon A contact lenses
Description: Habitual silicone hydrogel contact lenses
Study NCT03026257 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Habitual Multi-Purpose Solution (HMPS)
Description: Multi-purpose solution for contact lens care according to participant's habitual brand, used per manufacturer's instructions
Study NCT00417794 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Strattera
Description: escalating dosage: 0.5 mg/kg, 1.0 mg/kg, and 1.4 mg/kg titrated up or down according to adverse effects to therapy
Study NCT00417794 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with breakfast.
Study NCT01190254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine 2.5 mg
Description: asenapine 2.5 mg tablets for sublingual administration
Study NCT02472808 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: cTBNA with ROSE
Description: Patients will undergo conventional TBNA with rapid on site evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy
Study NCT02472808 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EBUS-TBNA without ROSE
Description: Patients will undergo EBUS-TBNA and endobronchial biopsy and transbronchial lung biopsy
Study NCT02472808 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: EBUS-TBNA with ROSE
Description: Patients will undergo EBUS-TBNA with rapid onsite evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy
Study NCT00351611 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lyrica (pregabalin)
Description: 150 mg twice a day, oral administration
Study NCT00351611 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Twice a day, oral administration
Study NCT00017095 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Study NCT00017095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Study NCT00017095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Study NCT00017095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: epirubicin hydrochloride
Study NCT00017095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin hydrochloride
Study NCT00017095 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluorouracil
Study NCT00017095 — intervention group
Intervention type: GENETIC
Group type: ACTIVE_COMPARATOR
Intervention: microarray analysis
Study NCT00017095 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: microarray analysis
Study NCT00017095 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: immunohistochemistry staining method
Study NCT00017095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Study NCT00017095 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: laboratory biomarker analysis
Study NCT00017095 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Study NCT00017095 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: biopsy
Study NCT00017095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: biopsy
Study NCT00017095 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional surgery
Study NCT00017095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: conventional surgery
Study NCT00017095 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: neoadjuvant therapy
Study NCT00017095 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: neoadjuvant therapy
Study NCT00017095 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study NCT02730975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AA Reduced dose-normal diet (A)
Description: Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined normal diet, described with specific caloric and fat content.
Study NCT02730975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AA reduced dose-fat diet (B)
Description: Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined fat diet, described with specific caloric and fat content.
Study NCT00017095 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Study NCT04965805 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: cold plasmaJet kINPen Med
Description: experimental, non-inferiority
Study NCT04965805 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Best practice wound dressings
Description: comparative,
Study NCT05260294 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural space identification with cervical epidural steroid injection employing CST and LORT.
Description: Cervical epidural procedure and epidural space recognition were performed utilizing the fluoroscopy only method. With this technique, needle navigation from the skin toward the epidural space is performed under contralateral oblique fluoroscopy. With the needle at the ventral interlaminar line, the contrast spread technique was employed for epidural space identification. After radiological confirmation of the epidural spread, LOR was tested using an Epidrum® device (Exmoor Innovations Ltd., Somerset, UK). Subsequently, accompanied by the radiology assistant, I observed the Epidrum for 30 seconds or more; if the Epidrum deflated, thus confirming LOR, the result was positive. However, if the device remained inflated, the result was reported as negative. The collected data was then analyzed.
Study NCT00573378 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-IFN-a2b
Description: Patients will receive pegylated interferon α-2b (Pegintron®) (PEG-IFN-α2b) 150 µg subcutaneously, once a week. Patients and/or caregivers identified by the patient will be taught how to perform subcutaneous injections of the PEG-IFN-α2b by trained nurses in the chemotherapy infusion center at the University of Michigan Comprehensive Cancer Center. Those patients who do not feel comfortable receiving the injections outside of the cancer center, or are deemed unreliable in administering injections per the training nurse, will return to the cancer center infusion room on a weekly basis to receive subsequent injections.
Study NCT01706406 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief psychoeducational intervention for female sexual arousal disorder
Description: four 1.5 hour long group psychoeducational sessions, spaced 2 weeks apart for a total of 8 weeks.
Study NCT01706406 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Brief psychoeducational intervention for female sexual arousal disorder
Description: four 1.5 hour long group psychoeducational sessions, spaced 2 weeks apart for a total of 8 weeks.
Study NCT04507295 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cerebral oximetry ( INVOS 5100 )
Description: in case of critical cerebra desaturation occurred which is defined as decrease in cerebral saturation by 20% from the base line the following will be done~1. Increase FIO2 up to 100%~2. Increase PEEP up to 5 cmH2O~3. Decrease insufflation pressure
Study NCT01614873 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Servo-i® ventilator, MAQUET,Critical Care, Sweden
Description: Electrical activity of the diaphragm will be obtained through a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden). Subject will be ventilated with a mouthpiece interface. NAVA will be compared to Pressure Support using the same ventilator. Once the pattern of breathing will be stabilized (10 minutes) in each condition (see arm) the following parameters will be recorded during 5 minutes and compared : tidal volume, inspiratory time, expiratory time, transcutaneous CO2 pressure, diaphragmatic Emg activity, delay between the inspiratory activity initiation and positive pressure initiation, delay between the end of the inspiratory effort and the end of pressurisation.
Study NCT01614873 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Servo-i® ventilator, MAQUET,Critical Care, Sweden
Description: Electrical activity of the diaphragm will be obtained through a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden). Subject will be ventilated with a mouthpiece interface. NAVA will be compared to Pressure Support using the same ventilator. Once the pattern of breathing will be stabilized (10 minutes) in each condition (see arm) the following parameters will be recorded during 5 minutes and compared : tidal volume, inspiratory time, expiratory time, transcutaneous CO2 pressure, diaphragmatic Emg activity, delay between the inspiratory activity initiation and positive pressure initiation, delay between the end of the inspiratory effort and the end of pressurisation.
Study NCT03411863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CES at rest
Description: CES will be delivered at rest at various intensities, in combination with either electrical stimulation over peripheral nerves or magnetic stimulation over the motor cortex.~This is an experiment designed to measure CES interactions with other central and peripheral nerve circuits.
Study NCT03411863 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CES at rest
Description: CES will be delivered at rest at various intensities, in combination with either electrical stimulation over peripheral nerves or magnetic stimulation over the motor cortex.~This is an experiment designed to measure CES interactions with other central and peripheral nerve circuits.
Study NCT03411863 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CES plus active hand or wrist movements
Description: CES will be delivered while the participant performs specific finger or wrist tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function.
Study NCT03411863 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CES plus active hand or wrist movements
Description: CES will be delivered while the participant performs specific finger or wrist tasks at different degrees of effort.~This is an experiment designed to detect momentary changes in muscle function.
Study NCT01348256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dendritic cells vaccine
Description: Vaccination with autologous dendritic cells loaded with autologous tumor antigens
Study NCT03383523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emodepside (BAY 44-4400)
Description: 2 tablets compared to the liquid formulation
Study NCT01055756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine + Pseudoephedrine sulfate
Description: Loratadine (5 mg) + Pseudoephedrine sulfate (120 mg)
Study NCT01055756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine + Pseudoephedrine sulfate
Description: Loratadine (5 mg) + Pseudoephedrine sulfate (120 mg)
Study NCT04394403 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based guided self-help based on CBT principles
Description: Individuals are provided basic rationale of CBT to deal with stress, worry, anxiety, dysphoria, sleep difficulties, emotion dysregulation, and memories all related to COVID-19
Study NCT01280643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT02730975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: AA normal dose-fasting conditions (C)
Description: Cycles of 28 days length of AA at approved doses (1000 mg) administered in fasting conditions.
Study NCT00843817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pulmozyme
Description: Pulmozyme® 2.5mg by inhalation
Study NCT03542825 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lactoferrin
Description: parallel use of the three drugs to compare the efficacy of each arm in prevention of anemia
Study NCT01190254 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asenapine 5.0 mg
Description: asenapine 5.0 mg tablets for sublingual administration
Study NCT01280643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT01280643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV
Study NCT01280643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV
Study NCT01280643 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV
Study NCT01280643 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Given IV
Study NCT01280643 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO
Study NCT01280643 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: mutation analysis
Description: Correlative studies
Study NCT01280643 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies
Study NCT01190254 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: asenapine-matched placebo tablets for sublingual administration
Study NCT02376946 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ActiPatch(TM)
Description: Assigned by randomization, this study group will be comprised of subjects that receive the PEMF ActiPatch(TM) treatment for postoperative management of pain and edema.
Study NCT02376946 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Assigned by randomization, this control group will be comprised of the subjects that receive a placebo patch as treatment for postoperative management of pain and edema.